Trial reportAnnals of the rheumatic diseases2003
Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women.
Trial report in Annals of the rheumatic diseases, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis.British journal of clinical pharmacology · 2004Pooled it
- Infusion of ibandronate once every 3 months effectively decreases bone resorption markers and increases bone mineral density in Chinese postmenopausal osteoporotic women: a 1-year study.Journal of bone and mineral metabolism · 2010Trial
- Effective doses of ibandronate do not influence the 3-year progression of aortic calcification in elderly osteoporotic women.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2005Trial
- Article
- Bone Turnover Markers: Basic Biology to Clinical Applications.Endocrine reviews · 2023Article
- Validation of the Surrogate Threshold Effect for Change in Bone Mineral Density as a Surrogate Endpoint for Fracture Outcomes: The FNIH-ASBMR SABRE Project.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2022Article
- Ibandronate for prevention and treatment of glucocorticoid-induced osteoporosis in rabbits.Rheumatology international · 2012Article
- Intravenous bisphosphonates for postmenopausal osteoporosis.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2010Article
- Management of osteoporosis among home health and long-term care patients with a prior fracture.Southern medical journal · 2009Review
- Review
- Advances in the management of corticosteroid-induced osteoporosis with bisphosphonates.Clinical rheumatology · 2007Review
- Use of intravenous bisphosphonates in osteoporosis.Current osteoporosis reports · 2007Article
- Quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women.Clinical interventions in aging · 2007Review
- Review
- Intravenous ibandronate in the treatment of osteoporosis: profile report.Drugs & aging · 2006Article
- Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.Drug safety · 2006Review
- Effective and rapid treatment of painful localized transient osteoporosis (bone marrow edema) with intravenous ibandronate.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2005Article
- Postmenopausal osteoporosis.Current osteoporosis reports · 2004Review
- Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2004Review
Corrections and comments
- Commented on by
Authors and funding
10 authors at 6 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the efficacy, safety, and dose response of three doses of ibandronate, given intermittently by intravenous (IV) injection every three months, in preventing postmenopausal osteoporosis. PATIENTS AND
methods629 postmenopausal women, categorised according to time since menopause and baseline lumbar spine (L1-4) bone mineral density (BMD), were enrolled into a multicentre, double blind, placebo controlled trial. They were randomly allocated to receive IV ibandronate 0.5 mg, 1 mg or 2 mg, or placebo every three months. All women received daily calcium supplementation.
resultsOne year's treatment with intermittent IV ibandronate injections produced a dose dependent gain in mean (SD) lumbar spine BMD from baseline of 2.5 (2.5)%, 1.8 (2.6)%, and 1.0 (2.8)% in the groups receiving 2 mg, 1 mg, and 0.5 mg ibandronate, respectively, compared with a loss of BMD of 0.4 (2.4)% in the women in the placebo group; p=0.0001 for each ibandronate dose v placebo. Highest BMD gains occurred in women with osteopenia receiving 2 mg ibandronate. Similarly, at the hip, all three doses of ibandronate produced significantly better gains in BMD than placebo (p<0.05), with the greatest gains in the women with osteopenia receiving the 2 mg dose. Ibandronate concomitantly and dose dependently suppressed markers of bone turnover in comparison with placebo, and injections were well tolerated.
conclusionIV ibandronate injections, given every three months, may be an effective alternative to oral bisphosphonates and hormonal therapy in the prevention of bone loss in postmenopausal women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.